MYD88 L265P mutation

The single point alteration in MYD88, L265P, is present in 67% to 100% of patients with lymphoplasmacytic lymphoma, and these patients typically have clinical manifestations of Waldenstrom macroglobulinemia (often designated LPL/WM). Therefore this test is used for
establishing the diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, as well as in distinguishing lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (low-grade B-cell lymphoma) from other subtypes

  • Sanger sequencing
  • Bone marrow / Blood
  • 7 days

Talk to us